| 证券代码 | OMED.O |
| 证券名称 | OncoMed Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-07-18 |
| 首发价格(元) | 17 USD |
| 首发数量(股) | 4800000 |
| 首发募资额(元) | 81,600,000.00 USD |
| 首发主承销商 | Jefferies LLC,Leerink Swann LLC |
| 货币单位 | USD |
| 公司名称 | OncoMed Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 800 Chesapeake Drive, Redwood City, California, USA |
| 成立日期 | 2004-07 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.oncomed.com |
| 电话 | +1 (650) 995-8200 |
| 传真 | +1 (650) 298-8600 |
| 公司简介 | OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), etigilimab (anti-TIGIT, OMP-313M32), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. |